WP 3.1 - MYOSCREEN

Erwann VENTRE

Successful comple­tion of all the subdeliverables for this WP :

WP 3.1.1 SMA MyoScreen model development

  • Primary myoblast sourcing
  • Myoblast banking
  • Validation of myotube differentiation on the MyoScreen platform

WP 3.1.2 SMA hypertrophy assay development

  • Treatment protocol optimization
  • Assay window validation
  • Selection of one donor for the screening

The development of the SMA MyoScreen model was successful, thanks to the primary muscle cells derived from SMA donors and stored in CBC Biotech-HCL. Two cell lines were used for assay development and validation. These samples met the banking criteria and were suitable for assay de­velopment. They were capable of differentiating into myotubes un­der physiological conditions and were compatible with MyoScreen technology. Optimal culture conditions were set to obtain sufficient fusion index in the 384-well format for hypertrophy assay development.

Everything has been optimized to proceed to the screening of small molecules libraries (WP 3.2)!